The therapeutic potential of siRNA-mediated targeting of MMP9, urokinase plasminogen activator receptor (uPAR), and cathepsin B, which play a major function in ECM degradation, was observed both in vivo and in vitro studies of prostate cancer. Here, PLAUR is linked to prostate carcinoma.